Obinutuzumab in the Management of Idiopathic Membranous Nephropathy

NCT05845762 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2023-05-10

No results posted yet for this study

Summary

To observe the efficacy and safety of obinutuzumab in Chinese population with idiopathic membranous nephropathy and guide clinical management.

Conditions

  • Idiopathic Membranous Nephropathy

Interventions

DRUG

Obinutuzumab Injection

1000mg intravenous injection

Sponsors & Collaborators

  • Qianfoshan Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-31
Primary Completion
2023-12-31
Completion
2023-12-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05845762 on ClinicalTrials.gov